Circulating Tumor Cells


HER2-positive circulating tumor cells in primary breast cancer patients with HER2-negative tumors

In metastatic breast cancer patients, the presence of circulating tumor cells (CTCs) in the blood predicts shorter progression-free survival and lower overall survival (1). Persistent CTCs after treatment also predict a lack of therapeutic response (2). Although the prognostic significance of CTCs in metastatic patients is well established, fewer studies have examined CTCs in primary… Read article →


CTCs as prognostic markers for metastatic breast cancer

Circulating tumor cells (CTCs) are tumor cells circulating freely in the peripheral blood of patients. The characterization of CTCs is considered as a real-time “liquid biopsy” that provides an ongoing picture of a patient’s cancer status, offering valuable insight into personalized anticancer therapy. CTCs are very rare and highly heterogeneous, possessing tumor-specific antigenic and genetic characteristics. One… Read article →

ILLU_0683_LiquidBiopsyMCF (2)

Tracking cancer with liquid biopsy

The advent of personalized medicine has created the need for simple, accurate and minimally invasive methods to repeatedly assess the genotype of patients’ tumors. Liquid biopsy, the use of body fluids as an alternative to tissue biopsy, has emerged as the next technological advance in cancer diagnosis and treatment. Three approaches to liquid biopsy have… Read article →